Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
VIYASHNSEVIYASH SCIENTIFIC LIMITED· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 11 Aug, 2026 · 13:05 IST

Q1 FY27 results, ESOP allotment, Vietnam subsidiary and Rs 400 cr AAHL investment

Results RestatedEmphasis Of MatterPat Growth 25pctResults View source PDFExplain this filing

VIYASH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-4.1%Reaction day
₹274.00
prior close
₹274.35
announcement price
In-mkt
timing
Nifty Microcap 250market-0.2%-4.0% vs market
Pharmaceuticals peers, median of 164sector+0.1%-4.2% vs sector

On the reaction day the stock moved 4.0 pts less than Nifty Microcap 250 and 4.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-3.3
10m
-2.7
15m
-4.4
30m
-4.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-4.1-0.2-4.0+0.1-4.2
Next day
-4.1+0.2-4.3-0.4-3.7
2d
-2.2+0.4-2.5+0.1-2.3
3d
-6.8+0.4-7.2-0.4-6.3
4d
-8.2+0.6-8.8-0.9-7.3
5d
-6.9+0.9-7.8-0.5-6.4
1w
-2.8+0.9-3.7-1.0-1.9
15d
-4.1+0.9-5.0-0.6-3.5
1m
-6.2+2.3-8.5+1.1-7.4
2m
-14.2-1.1-13.1-3.1-11.2
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1 FY27 consolidated revenue rose to Rs 9,463.6 mn from Rs 7,916.4 mn (restated YoY); PAT jumped to Rs 792.9 mn from Rs 368.5 mn. Standalone revenue Rs 3,536.9 mn, PAT Rs 209.2 mn. Auditors gave unmodified review. Board allotted 10.3 lakh ESOP shares at Rs 101, approved Vietnam step-down subsidiary, and converting Rs 400 cr intercompany loan into equity of AAHL subsidiary.

Likely market impact

Strong consolidated PAT growth of over 115% YoY. New Vietnam expansion and Rs 400 cr capital infusion in subsidiary aimed at growth. Minor equity dilution from ESOPs.